Search titles, impact clusters, countries, organizations and the full text of every analysis.
26 stories found
This Nature Portfolio perspective argues that self-driving labs are moving from isolated autonomous experiments toward multi-agent AI systems that manage full research campaigns, including experiment selection, lab coordination, resource constraints, and collaboration among specialized agents.
The U.S. government has committed more than $5 billion to expand the Genesis Mission, a multi-agency effort that combines federal datasets, Department of Energy supercomputers, research facilities, and AI tools. More than 15 agencies and 278 selected projects will target problems including chronic disease, pediatric cancer, drug discovery, resilient building materials, transportation maintenance, energy, manufacturing, agriculture, and national security.
A Nature Sensors review argues that AI-powered closed-loop wearables could move healthcare devices beyond passive data collection by connecting continuous biosensing directly to AI-guided decisions and therapeutic intervention. The authors emphasize that clinical value depends on the coordinated system—sensing, control, treatment, and human oversight—not any component alone. Long-term interface stability, robust control, transparent safety mechanisms, and evidence of patient benefit remain prerequisites for scalable use.
Researchers reviewed 239 peer-reviewed studies on AI-supported deep-brain stimulation and found a pronounced gap between reported algorithmic performance and clinical readiness. External validation remained rare, evaluations were predominantly retrospective and single-centre, and more than one-quarter of studies used small, high-dimensional datasets with elevated overfitting risk; most systems therefore remained at early-to-intermediate technology-readiness levels.
University of Sydney and UC San Diego researchers reviewed 82 studies combining medical imaging, clinical records, and other health-data modalities. They find that most explanations still assign importance to each modality separately and rely on post-hoc techniques that leave the model’s cross-modal reasoning opaque; standardized evaluation was absent from most studies, qualitative assessment predominated, and only a minority provided sufficiently reproducible public code.
Australia’s Assistant Minister for Science, Technology and the Digital Economy, Andrew Charlton, used a University of Sydney AI Safety Forum speech to frame advanced AI as a “control problem,” citing evidence from the 2026 International AI Safety Report that frontier models show early signs of deception, cheating, and situational awareness. He argued that misalignment becomes a public-safety issue when AI systems draft legislation, screen welfare claims, manage power grids, or otherwise operate inside high-stakes infrastructure.
Harvard/Beth Israel-led authors estimate that roughly 27% of AI users may already use AI for mental-health support, while stressing that the true range is hard to pin down because surveys use inconsistent definitions and mixed data sources. The paper moves beyond anecdotal harm cases and shows it moves the discussion beyond anecdotal harm cases and shows that even basic prevalence measurement is unstable.
Reviewing 72 studies of reinforcement-learning systems for sepsis treatment, the authors found that every study was retrospective, 58 studies—80.6%—relied on the same MIMIC critical-care database, and only 10 used private datasets. Although many papers claimed that AI-derived treatment policies outperformed clinicians, variation in how patient states, treatment actions, rewards, and counterfactual outcomes were defined made those comparisons difficult to validate.
Researchers combined deep learning and molecular docking to design candidate binders for the SARS-CoV-2 Mac1 protein, then synthesized and experimentally confirmed selected compounds using NMR spectroscopy and X-ray crystallography. The resulting molecules improved on the original fragment hits, although their binding affinities—(K_D) values of 299–990 μM—indicate early-stage chemical starting points rather than therapeutic candidates.
Stanford, Harvard and UCLA-affiliated authors synthesize evidence across diagnostic, treatment-management and care-adjacent agent deployments. They find that current implementations remain concentrated in administrative workflows, although agents are beginning to appear throughout the clinical journey.
The newly released agenda consolidates proposed AI legislation around six immediate-impact areas: worker power and workplace surveillance, child and adolescent safety, algorithmic discrimination and civil rights, human oversight in healthcare, data-center energy and environmental burdens, and broader distribution of AI-generated wealth. Proposals include limits on automated employment decisions, workplace surveillance protections, stronger safeguards for children interacting with chatbots, bias oversight, human-centered healthcare requirements, and legislation requiring data centers to finance sufficient clean-energy generation and storage.
The Department for Science, Innovation and Technology published an independent Lancaster University review that mapped 9,109 peer-reviewed AI-security papers from 2021 through January 2026 across 12 lifecycle themes. Despite rapid publication growth, the review identifies major blind spots in formal verification of training data and model-weight integrity, third-party model provenance, the interaction between AI-specific and conventional IT attack surfaces, end-user and shadow-AI risks, and secure retirement or disposal of frontier models.
This Duke/NYU-linked qualitative study of 40 patients finds that patients value AI-drafted portal replies mainly for efficiency, but their acceptance is conditional on clinician review, accountability, and disclosure. Patients did not uniformly want “more empathy”; they wanted tone, length, and detail to match the stakes of the message, with lower-stakes refills treated differently from serious clinical concerns.
This review includes authors from MIT, Stanford, Imperial College London, Toronto/Vector, UC Davis, and other institutions, and frames AI as a way to speed sustainable food design across ingredient discovery, formulation, fermentation, sensory science, production, and recipe generation. It is especially significant because it treats food as a “programmable biomaterial” and calls for self-driving labs and deep reasoning models that jointly optimize nutrition, sensory quality, and environmental impact.
A Harvard/Broad/MIT-linked team introduced COMPASS, a pan-cancer foundation model that predicts immune-checkpoint-inhibitor response from tumor transcriptomes and interpretable immune concepts. The model was trained on 10,184 tumors across 33 cancer types and reportedly outperformed 22 existing approaches across 16 clinical cohorts covering seven cancers and six immunotherapy agents, with predicted responders showing longer overall survival.
OpenAI released GeneBench-Pro, a research-level benchmark for testing whether AI agents can reason through ambiguous computational-biology and translational-medicine problems rather than simply answer clean exam-style questions. The benchmark includes 129 expert-created questions across genomics, quantitative biology, pharmacogenomics, and clinical/translational domains; OpenAI reports GPT5.6 Sol reaching 28.7% overall pass rate and 31.5% in Pro mode, while GPT5 scored below 5%.
Stanford researchers used generative AI trained on 2,216 human-designed burger recipes and 146 ingredients, then sampled one million recipes to optimize taste, environmental impact, and nutrition. In a blinded restaurant sensory evaluation with 101 participants, one mushroom-based formulation had an environmental-impact score more than an order of magnitude lower than the Big Mac benchmark, while a bean-based burger nearly doubled the nutritional score and reduced environmental impact by a factor of six.
Nature Biomedical Engineering published a lung-cancer pathology AI paper introducing TRUECAM, a framework that detects out-of-scope inputs, filters ambiguous regions, and uses conformal prediction to control error rates; the authors report gains in accuracy, robustness, interpretability, data efficiency, and fairness across datasets and foundation models. its significance is less “AI replaces diagnosis” than “AI deployment requires uncertainty, fairness, and error-control layers.”
This Oxford-led npj Digital Medicine review screened 17,463 records and included 140 empirical studies of human-AI collaboration in healthcare from January 2015 through October 2025. It finds that the evidence base is concentrated in diagnostic interpretation, while triage, therapeutic, administrative, and system-level workflows remain thinner; it also notes that AI benefits depend heavily on task fit, workflow integration, training, and calibrated trust.
The NUS/Harbin-led team identifies a domain-specific form of generative-AI hallucination: molecular candidates can receive strong predicted binding scores while violating basic chemistry or producing physically impossible atomic arrangements. Its DrugRPG framework incorporates chemical-foundation-model priors and differentiable physical constraints during molecule generation, reducing severe steric clashes by 65.4% relative to the reported state-of-the-art baseline and increasing by 28.6% the share of generated candidates meeting combined potency, stability, and synthetic-feasibility criteria.
The authors argue that AI’s effect on aggregate healthcare spending will not follow automatically from technical productivity gains: payment incentives, organizational priorities, implementation capacity, and management decisions will determine whether efficiency improvements lower costs, increase service volume, or are absorbed by providers. Even organizations financially rewarded for reducing expenditures may struggle to translate AI-supported productivity into lower spending because of internal workflows, professional incentives, and institutional dynamics.
Researchers affiliated with Harvard Medical School, the University of Pennsylvania, and the University of Toronto developed a noise-adapted single-lead ECG model for detecting left-ventricular systolic dysfunction in pediatric and congenital-heart-disease populations. The study used an internal cohort of 70,226 patients and external cohorts comprising 42,984 patients at Children’s Hospital of Philadelphia and 284 patients at Toronto General Hospital, reporting strong performance across different congenital conditions, age groups, racial groups, and health systems.
The paper introduces Biomni, a general-purpose biomedical agent that can search literature, formulate hypotheses, select datasets and specialized tools, write analytical code, interpret results, and propose subsequent experiments within an integrated workflow. Stanford reports that a prototype is already used by more than 10,000 laboratories; in one example, it processed over 450 wearable-health files and generated plausible findings in 40 minutes, compared with an estimated 60 or more hours of human work.
Cambridge Judge highlighted peer-reviewed studies examining trust in healthcare AI. Choi et al. found that AI-involved hospital adverse events increase perceived hospital responsibility and complaint or legal-action intentions unless physician-AI collaboration is visibly interactive.
This multicenter study involved more than 400 physicians across seven specialties and compared human physician evaluation of LLM outputs with AI-agent evaluation configured to mirror physician assessment. AI evaluators were efficient and directionally aligned with physicians, but did not fully capture human clinical judgment and should not replace physician-centered evaluation.
A new Nature News & Views piece highlights two 2026 Nature papers showing AI agents moving from literature support toward hypothesis generation, experiment planning, and data analysis. One paper introduces Robin, a multi-agent system that generated hypotheses, proposed experiments, interpreted results, and identified therapeutic candidates for dry age-related macular degeneration; another introduces Google/DeepMind’s Gemini-based Co-Scientist, with affiliations including Stanford University School of Medicine and Imperial College London, and reports experimentally validated biomedical hypotheses including acute myeloid leukemia drug-repurposing and combination-therapy candidates.